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square and Student t- tests for categorical and continuous variables, respectively. 
The effect of the selection of P2Y12 drugs on the time-to-first hospital re-admission 
was determined using a Cox-proportional hazard regression model. We controlled 
for potential confounders whose p-values at the baseline comparison were less 
than 0.1. Results: A total of 9698 patients received PCI with a primary diagnosis 
of ACS, and started prasugrel (n= 7095) or ticagrelor (n= 2603). The ticagrelor treated 
group was older and more likely to have a diagnosis of intracranial hemorrhage, 
cerebrovascular accident, cardiac disorders and renal disorders than the prasugrel 
group. The observed 365-day hazard ratio (HR) of re-admission for ticagrelor was 
1.056 [95% CI: 0.867, 1.285] which was unchanged after controlling for the potential 
confounders (HR: 1.056 [95% CI: 0.867 – 1.286]). ConClusions: The selection of 
third-generation antiplatelet agents following PCI was not associated with a clini-
cally or statistically significant reduction in hospital-readmission.
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Can Data Simulation HelP eValuate Hta outComeS oVer time anD 
FaCilitate early DeCiSion-making? a CaSe StuDy oF tiCagrelor in 
aCute Coronary SynDrome in tHe uk
Dequen P, Cooper NJ, Abrams K
University of Leicester, Leicester, UK
BACkgRound: In October 2011, the National Institute for Health and Care 
Excellence (NICE) recommended the use of ticagrelor in adult patients presenting 
with acute coronary syndrome (ACS) in England and Wales. The relative effective-
ness and cost-effectiveness of ticagrelor compared to clopidogrel—the current 
standard of care in the NHS—were based on results from one large multicentre 
study including over 18,000 ACS patients. Patients were recruited from October 
2006 through to July 2008 and primary trial data analysis, published in September 
2009, demonstrated that ticagrelor significantly reduced the rate of death, myo-
cardial infarction (MI), and/or stroke versus clopidogrel. Delays in completing 
and reporting on RCTs can impede access to new valuable treatments; however, 
data simulation may allow for the continuous modelling of trial results and sup-
port early HTA submissions. oBjeCtives: Using a data simulation approach to 
estimate the relative effectiveness of ticagrelor vs. clopidogrel from recruitment 
to final analysis, we explore whether a trial design with shorter follow-up or the 
publication of an interim analysis could have resulted in a positive NICE decision 
at an earlier time point. Methods: Time-to-event data was extracted from pub-
lished Kaplan-Meir curves and individual patient data was simulated assuming 
censoring and recruitment distributions. The relative effectiveness of ticagrelor 
was assessed as a continuum from 2006 to 2009; and the probability of ticagrelor 
being cost-effective in the UK was also evaluated over time using a trial-based 
economic model. Results: Despite increased uncertainty around the probabili-
ties of death, MI and stroke estimated from immature trial data; results suggest 
that ticagrelor was a cost-effective alternative to clopidogrel before the original 
completed 12 months follow-up. ConClusions: Data simulation allowed us to 
evaluate HTA outcomes prior to the original planned analysis which, in retrospect, 
could have led to an earlier NICE recommendation for ticagrelor in ACS.
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aSPirin VerSuS CloPiDogrel in PatientS witH iSCHemiC Stroke: a 
CoSt anD eFFeCtiVeneSS ComPariSon From Beijing meDiCal inSuranCe 
DataBaSe
Wen L1, Wu J2, Yang L1
1Peking University, Beijing, China, 2Bayer, Beijing, China
oBjeCtives: To compare the cost and effectiveness of aspirin and clopidogrel 
in ischemic stroke(IS) patients from data of Beijing medical insurance data-
base. Methods: We randomly selected 10% of patients diagnosed as IS the 
first time during January 2012- December 2012 and then followed their inpatient 
records and prescription records to September 2013 from Beijing urban employees 
and residents medical insurance database. We divided these patients into 5 groups 
according to their drug utilization records during the observation period. Patients 
were divided into 5 groups according to the proportion of aspirin prescription by 
100.0%, 60.1-99.9%, 40.0-60.0%, 0-39.9% and 0(clopidogrel only). We compared the 
rate of recurrences, cost of anti-platelet drugs and rate of hemorrhage events in 
different drug utilization groups. The Kruskal-Wallis test and Bartlett’s test were 
used in the analysis. Results: 4301 patients were identified(age 68.29±13.94, 
male 63.19%), 1477 (34.34%) patients used aspirin only, 1938 (45.06%) patients used 
60-100% aspirin, 465 (10.81%) patients used 40-60% aspirin, 335 (7.78%) patients 
used aspirin 0-40% and 86 (2.01%) patients used clopidogrel only. patients with 
only aspirin recurred less than patients with both aspirin and clopidogrel pre-
scription, patients with 60-100% aspirin prescription recurred less than patients 
with less aspirin prescription. patients with aspirin prescription only spent less 
on anti-platelet drugs than that of patients with both aspirin and clopidogrel 
prescription(p< 0.01),. The rates of hemorrhage events for IS patients of different 
drug groups showed no significant difference(p> 0.05). ConClusions: IS patients 
used more aspirin for anti-platelet treatment. The cost of anti-platelet drugs and 
rate of recurrence of patients who used aspirin only was lower, while no significant 
difference was found in hemorrhage events rates among different drug groups.
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a mixeD treatment ComPariSon (mtC) to ComPare tHe eFFiCaCy 
oF anti-tHromBotiC agentS in tHe aCute treatment oF VenouS 
tHromBoemBoliSm (Vte) in PatientS witH aCtiVe CanCer
Edwards SJ, Wakefield V, Karner C
BMJ, London, UK
oBjeCtives: New oral anticoagulants (NOACs) are available for the treatment and 
prevention of VTE but evidence on their clinical effectiveness compared with existing 
treatments is limited. This research compared the clinical effectiveness of dabigatran, 
rivaroxaban, adjusted standard dose warfarin (warfarin), and low molecular weight 
heparin (LMWH) in people with active cancer following VTE. This research was con-
to apixaban. One-way and probabilistic sensitivity analyses indicated that model 
conclusions were robust over a wide range of inputs. ConClusions: Apixaban 
appears to be a dominant alternative to LMWH/edoxaban for the treatment and 
prevention of VTE.
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real-worlD eFFeCtiVeneSS oF amloDiPine/ValSartan/
HyDroClorotHiaziDe Single-Pill ComBination in tHe treatment oF 
PatientS witH eSSential HyPertenSion
Viriato D1, Antunes M2
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oBjeCtives: Uncontrolled hypertension remains a major problem for health care 
systems worldwide, being strictly related to a persistently elevated burden of car-
diovascular morbidity and mortality. Because of the multifactorial nature of hyper-
tension, most patients require combination therapy to achieve blood pressure (BP) 
control. This analysis aimed to further investigate the effectiveness of amlodipine/
valsartan/hydrochlorothiazide (A+V+H) single-pill combination in lowering the BP 
of hypertensive patients, previous assessed in an observational study. Methods: 
This analysis was based on a data registry collected in a prospective, open-
label, observational study conducted in 7132 patients diagnosed with essential 
hypertension and for whom treatment with A+V+H was indicated according to 
clinical practice. The observational period was 3 months. Descriptive analysis, 
hypothesis testing and linear regression models were performed. Results: The 
reduction in systolic blood pressure (RSP) between baseline and last visit was 
23.73±17.51 (mean±SD) while the reduction in diastolic blood pressure (RDP) was 
11.34±10.63 mmHg (mean±SD). A t-test showed that both reductions are statisti-
cally significant (p< < 0.001). Multiple linear regression models were fitted to RSP 
and RDP, to assess the influence of patients’ characteristics, comorbidities and 
previous treatment (R2 = 0.11 and 0.13, respectively). ConClusions: Although 
significant, the model covariates were not sufficient to explain the reduction 
in SP and DP (11% and 13% explained, respectively) found between the base-
line and last visit. Since most of the variables known as relevant to character-
ize hypertension were included in the study, the results allow to conclude that 
reduction found is mainly explained by the treatment with A+V+H single-pill 
combination.
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a mixeD treatment ComPariSon (mtC) to ComPare tHe eFFiCaCy oF 
anti-tHromBotiC agentS in treatment anD SeConDary PreVention 
oF VenouS tHromBoemBoliSm (Vte) in PatientS witH DeeP Vein 
tHromBoSiS (DVt)
Edwards SJ, van Velthoven MH, Crawford F
BMJ, London, UK
oBjeCtives: New oral anticoagulants (NOACs) are available for the treatment 
and prevention of VTE, but evidence on their clinical effectiveness compared 
with existing treatments is limited. We compared the clinical effectiveness of 
edoxaban, dabigatran and rivaroxaban using adjusted standard dose warfarin 
(warfarin) as a common comparator in patients with index DVT. This research 
was conducted during a review of the company’s submission (CS) to the National 
Institute for Health and Care Excellence (NICE) Single Technology Appraisal pro-
gramme for the oral direct factor Xa inhibitor, edoxaban. Methods: Randomised 
controlled trials (RCTs) for inclusion were identified using the CS for edoxaban 
(as part of Technology Appraisal [TA] 662). We assessed RCTs for comparability 
based on patient population, disease severity, and treatments received. We con-
ducted a Bayesian MTC and explored fixed and random effects models. Odds ratio 
(OR) was the summary statistic for VTE recurrence and major bleed. Results: 
The network of five RCTs formed a “radiating star”. The Deviance Information 
Criterion (DIC) and the residual deviance with the number of unconstrained 
data points for both outcomes showed fixed and random effects models were 
an equally good fit. Due to the small number of studies and the shape of the 
network, the results from the fixed effects model are presented. Results com-
pared to warfarin were (OR> 1 favours warfarin): VTE recurrence edoxaban OR 0.95 
(95% Credible Interval [95%CrI]: 0.62–1.40), dabigatran OR 1.27 (95%CrI: 0.78–1.97), 
rivaroxaban OR 0.64 (95%CrI: 0.40–0.96); major bleed edoxaban OR 0.84 (95%CrI: 
0.48–1.35), dabigatran OR 0.83 (95%CrI: 0.50–1.31), rivaroxaban OR 0.92 (95%CrI: 
0.37–1.90). ConClusions: Rivaroxaban demonstrated a 36% reduction in risk 
of VTE recurrence compared to warfarin that was statistically significant at the 
5% level. We did not identify other significant differences either when comparing 
NOACs to warfarin or when comparing NOACs with each other.
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ComParatiVe eFFeCtiVeneSS oF tiCagrelor VS. PraSugrel in PatientS 
witH aCute Coronary SynDrome
Kim K, Lee TA, Ardati AK, Didomenico RJ, Touchette D, Walton SM
University of Illinois at Chicago, Chicago, IL, USA
oBjeCtives: Randomized controlled trials have provided evidence that both 
prasugrel and ticagrelor can reduce complications in patients with acute coronary 
syndrome (ACS). However, no head-to-head comparisons were performed between 
these third-generation drugs. The aim of this study was to compare the hospital 
admission rates between patients receiving ticagrelor and prasugrel during post 
percutaneous coronary intervention (PCI). Methods: A Retrospective cohort 
study was designed to compare all cause hospitalization over 365 days post PCI 
discharge. Patients who received PCI with an ACS hospitalization between January 
2012 to December 2013 were extracted from the Truven Health Analytics MarketScan 
database. Eligible patients filled either a prasugrel or ticagrelor prescription within 
14 days from the discharge date. To be included in the analytic cohort, patients 
needed to be continuously enrolled in the data over six-months prior to the index 
admission, and comorbid conditions over that period were assessed using Chi-
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network meta-analySiS oF VariouS treatment StrategieS in 
reSiStant HyPertenSion
Makai P, intHout J, Grutters JP, Deinum J, Jenniskens K, van der Wilt GJ
Radboudumc, Nijmegen, The Netherlands
oBjeCtives: Currently, the most commonly applied approach to treatment of resist-
ant hypertension (TRH) is adding on mineralocorticoid receptor antagonists (MRAs) 
such as spironolactone to existing medication therapy. Newer treatment alterna-
tives for treating resistant hypertension were developed, however comparative 
effectiveness of these add-on strategies and MRAs is not established. Our objective 
is to perform a network-meta analysis of add-on treatment alternatives for MRAs 
in TRHTN and thus establish comparative effectiveness in terms of SBP and DBP 
reduction. Methods: Recent meta-analyses for renal denervation (RDN) and placebo 
effect were supplemented with a systematic search for MRAs in TRHTN. Newer renal 
denervation articles were identified using Pubmed searches. Search terms included 
Randomized control trials (RCT), TRH, MRAs. We Independently extracted data using 
a pre-defined data extraction form, including Cohrane study quality indicators and 
the GRADE criteria. Network meta-analysis techniques were used to compare the 
effects of add-on treatment alternatives for TRHTN, using spironolactone as a com-
mon comparator. Results: We identified 16 articles which met our inclusion criteria. 
The results show that lack of add-on medication therapy leads to markedly higher 
blood pressure measurements than spironolactone, office SBP 24 [95% CI 2; 48] DBP 
7.4 [-2.9; 18]. While add-on placebo medication results in significantly higher blood 
pressure than add-on spironolactone, SBP 19 [5.7; 32] DBP 8.3[2.3; 14], add-on spirono-
lactone’s blood pressure reducing effects equal those of add-on sham operations SBP 
0.58 [-28; 29] DBP 0.36 [-12; 13]. ConClusions: Currently, no active, add-on treatment 
strategy for TRHTN seems more effective than spironolactone. In addition, being the 
only effective active treatment strategy, research into future medicinal alternatives 
in TRHTN should use spironolactone as an active comparison, and as an obligatory 
background drug when investigating the effectiveness of device-based alternatives. 
Furthermore, trials investigating device-based alternatives such as renal denervation 
should always include sham procedure as a comparator.
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aSPirin VerSuS CloPiDogrel in PatientS witH aCute myoCarDial 
inFarCtion: a CoSt anD eFFeCtiVeneSS ComPariSon From Beijing 
meDiCal inSuranCe DataBaSe
Wen L1, Wu J2, Yang L1
1Peking University, Beijing, China, 2Bayer, Beijing, China
oBjeCtives: To compare the cost and effectiveness of aspirin with that of clopi-
dogrel in acute myocardial infarction(AMI) patients from data of Beijing medical 
insurance database Methods: We randomly selected 10% of patients diagnosed 
as AMI the first time during January 2012- December 2012 and then followed their 
inpatient records and prescription records to September 2013 from Beijing medical 
insurance database. We divided these patients into 5 groups according to their drug 
utilization records during the observation period. 1239 patients were divided into 
5 groups according to the proportion of aspirin prescription by 100.0%, 60.1-99.9%, 
40.0-60.0%, 0-39.9% and 0(clopidogrel only). We compared the rate of recurrences, 
cost of anti-platelet drugs and rate of hemorrhage events in different drug utiliza-
tion groups. The Kruskal-Wallis test and Bartlett’s test were used in the analy-
sis. Results: 1239 patients were identified(age 65.69±15.51, male 73.69%), 63 (2.54%) 
patients used aspirin only, 761 (61.42%) patients used aspirin more(60-100%), 289 
(23.33%) patients used 40-60% aspirin, 116 (9.36%) patients used aspirin 0-40% and 
10 (0.83%) patients used clopidogrel only. The MI recurrence rates for patients of 
different prescription groups were significantly different(p< 0.01), patients with only 
aspirin utilization recurred less than that of patients with 60-100% aspirin and 
40-60% aspirin prescription, patients with 0-40% aspirin prescription recurred less 
than that of patients with 60-100% aspirin prescription. The cost of anti-platelet 
drugs for patients of different drug groups was significantly different(p< 0.01), The 
hemorrhage rate of patients with only aspirin prescription was higher than that of 
patients with two drugs. ConClusions: A small proportion of AMI patients used 
only one drug for anti-platelet treatment, while most patients used both aspirin and 
clopidogrel. Patients who used aspirin only had lower cost of anti-platelet drugs, 
lower rate of recurrence and higher rate of hemorrhage events. Further studies 
on cost-effectiveness for aspirin and clopidogrel would provide moret evidence.
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long-term inCreaSeD inPatient anD outPatient ViSitS aSSoCiateD 
witH CarDioVaSCular eVentS: a large uniteD StateS real worlD 
StuDy
Fox KM1, Wang L2, Quek RG3, Gandra SR3, Li L2, Baser O4
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oBjeCtives: To evaluate the burden to patients and the healthcare system associ-
ated with a new cardiovascular event (CVEs) up to 3 years post-new CVE among 
high-risk hyperlipidemia patients. Methods: Using the IMS LifeLink PharMetrics 
Plus commercial claims database, this retrospective cohort study included high CV 
risk hyperlipidemia patients with and without a new CVE between 01/01/2006 and 
06/30/2012. CVEs included primary inpatient claims for myocardial infarction (MI), 
unstable angina (UA), ischemic stroke (IS), transient ischemic attack, revascularization 
and heart failure. Patients were stratified into two CV risk cohorts: history of cardio-
vascular disease (CVD) [MI, UA, coronary artery bypass graft, percutaneous coronary 
intervention, IS] and coronary heart disease risk equivalent (CHD RE) [peripheral 
artery disease, abdominal aortic aneurysm, coronary artery disease, diabetes, dys-
lipidemia]. Propensity score matching was applied to compare the burden among 
patients with and without a new CVE, ranging from 1 month through 3 years post-CVE 
date. Results: Using the IMS LifeLink PharMetrics Plus commercial claims data-
base, this retrospective cohort study included high CV risk hyperlipidemia patients 
ducted during a review of the company’s submission (CS) to the National Institute for 
Health and Care Excellence (NICE) Single Technology Appraisal programme for the 
oral direct thrombin inhibitor, dabigatran. Methods:: Randomised controlled trials 
(RCTs) for inclusion were identified using the CS for dabigatran (as part of Technology 
Appraisal [TA]327), and two similar submissions for rivaroxaban (TA261 and TA287). 
RCTs were assessed for comparability based on patient population, disease severity, 
and treatments received. A Bayesian MTC was conducted, and fixed and random 
effects models were explored. Odds ratio (OR) was chosen as the summary statistic for 
VTE recurrence and major bleed. Results: The network of 9 RCTs formed a “radiating 
star”. The fixed effects model had the lowest deviance information criterion (DIC) for 
VTE recurrence and major bleed and so was chosen as the best-fitting model. There 
was reasonable agreement between the number of unconstrained data points and 
the residual deviance for both outcomes. Results compared to dabigatran were (OR> 1 
favours dabigatran): VTE recurrence LMWH OR 0.96 (95% Credible Interval [95%CrI]: 
0.15–3.37), rivaroxaban OR 1.29 (95%CrI: 0.12–5.42), warfarin OR 1.87 (95%CrI: 0.31–6.45); 
major bleed LMWH OR 0.85 (95%CrI: 0.15–2.67), warfarin OR 0.74 (95%CrI: 0.15–2.15). 
No data were available on major bleed for rivaroxaban in people with active can-
cer. ConClusions: There were no significant differences in the outcomes evaluated. 
However, the available evidence suggests that LMWH may have the lowest risk of VTE 
recurrence in the treatments assessed.
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aSSoCiation Between aDHerenCe to eViDenCe-BaSeD Heart Failure 
Drug treatment anD one-year all-CauSe HoSPitalization anD all-
CauSe mortality
Moisan J1, Girouard C1, Demers E2, Perez-Herrera N2, Zaour N3, Grégoire J1
1Laval University, Quebec, QC, Canada, 2Centre de recherche du CHU de Québec, Quebec, QC, 
Canada, 3Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada
oBjeCtives: To assess the association between adherence to heart failure (HF) 
evidence-based treatment (i.e. β -blocker + angiotension-converting enzyme inhibi-
tor or angiotensin receptor blocker or hydralazine + isosorbide dinitrate), and 1) 
one-year all-cause hospitalization and 2) one-year all-cause mortality, among 
people newly diagnosed for HF. Methods: We conducted two nested case-control 
studies using Quebec (Canada) medico-administrative data. We selected cases and 
controls in a cohort made of Quebec residents ≥ 18 years who had a first diagnosis 
of HF between 01/01/2000 and 12/31/2009 and who did not use HF evidence-based 
treatment before their diagnosis. Cases were those hospitalized or who died in 
the year after HF diagnosis. Each case was randomly matched to 4 to 10 controls 
using incidence density sampling. Adherence to HF evidence-based treatment 
was assessed using the proportion of days covered (PDC). Odds ratios (OR) were 
calculated using conditional multivariable logistic regressions. Results: Among 
the 125,622 individuals in the cohort, 70,483 (56.1%) were hospitalized and 19,915 
(15.9%) died during the first year after diagnosis. Only 7.5% of hospitalization cases, 
9.5% of their controls, 6.9% of death cases and 11.6% of their controls had a PDC 
≥ 80%. Compared to those with a PDC ≥ 80%, patients who had a PDC > 0% and 
< 80% (OR= 1.39 (95% CI= 1.33-1.46) or a PDC = 0% (OR= 1.53 (1.48-1.58) were more 
likely to be hospitalized within the first year after diagnosis. Similarly, compared 
to those with a PDC ≥ 80%, patients who had a PDC > 0% and < 80% (OR= 1.72 (95% 
CI= 1.59-1.86) or a PDC = 0% (OR= 2.26 (2.13-2.40) were more likely to die during the 
year after diagnosis. ConClusions: Adherence to HF evidence-based treatment 
is suboptimal. A low adherence could increase the risk of hospitalization and have 
a detrimental effect on survival of HF patients.
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SyStematiC reView anD meta-analySiS oF SelF-monitoring anD 
SelF-management oF antiCoagulation tHeraPy witH Vitamin k 
antagoniStS
Locatelli I, Marjanovic I, Janzic A
University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia
oBjeCtives: The introduction of prothrombin time (INR) point-of-care devices 
permits patient self-testing of the INR values and subsequently, also self-adjust-
ment of the dosing regimen. The purpose of this systematic review was to evaluate 
recent findings regarding the effects of self-monitoring and self-management of 
anticoagulation therapy with vitamin K antagonists (coumarins) compared to the 
standard ambulatory care. Methods: A comprehensive literature search using 
OVID MEDLINE (1946 – April 2015) and EMBASE (1974 – April 2015) databases was 
performed. Selection criteria were restricted to randomized controlled clinical tri-
als evaluating self-monitoring or self-management with standard care as control. 
Meta-analysis was performed in Review Manager Computer program (Version 
5.3.) using a fixed-effect model with the Mantel-Haenszel method to calculate 
the pooled risk ratios (RR) and their 95% confidence interval (CI) of the following 
clinical outcomes: thromboembolic events, major haemorrhage, and all-cause 
mortality. Potential heterogeneity was assessed with I2 statistics. Results: In 
addition to the 2010 Cochrane review (Self-monitoring and self-management of 
oral anticoagulation), 10 novel randomized trials were identified; in 3 of them 
self-monitoring was evaluated, while in the other 7 studies self-management 
was assessed. Until the April 2015, self-monitoring and self-management was 
evaluated in 10 (4313 participants) and 19 (5413 participants) randomized tri-
als, respectively. Self-management was associated with significant reductions in 
both thromboembolic events (RR= 0.48, 95%CI: 0.35–0.65, p< 0.001) and mortality 
(RR= 0.70, 95%CI: 0.49–0.99, p= 0.046), while no significant effect on major bleedings 
was found (RR= 1.03, 95%CI: 0.77–1.38). In contrast to the 2010 Cochrane review 
no significant benefit of self-monitoring could be confirmed: the RRs were 0.91 
(95%CI: 0.71–1.16), 0.91 (95%CI: 0.75–1.10), and 0.94 (95%CI: 0.75–1.17) for the throm-
boembolic events, major bleedings, and mortality, respectively. ConClusions: 
Compared to the standard ambulatory care, patient self-management of the INR 
values shows beneficial effects on their anticoagulant therapy. Moreover, self-
management better improves the probability of the occurrence of thromboembolic 
events than self-monitoring.
